Sep 25 2006
Attention Business Editors: NeuroMedix will present a company update at the BioFinance 2006 conference in Toronto on May 4, 2006
TORONTO, May 3 /CNW/ - NeuroMedix Inc. (”NeuroMedix”) (TSXV: NMX) today
announced that Dr. Mark Pearson, Chief Executive Officer of NeuroMedix, will
present a company update at the BioFinance 2006 conference in Toronto.
Dr. Pearson’s presentation is scheduled for May 4, 2006 at 11:30 a.m. EDT at
the Toronto Marriott Eaton Centre.
NeuroMedix, a company focused on the development of therapeutic agents
for the treatment of neuroinflammatory diseases, has commenced cGMP
manufacture of its lead compound, Minozac, and expects to initiate
pre-clinical toxicology studies, in preparation for a Phase I clinical trial,
in the next few weeks. NeuroMedix’s clinical development plan is currently
focused on Alzheimer’s disease, based on the efficacy of Minozac in preventing
the release of neurotoxic cytokines from glia in a mouse model of Alzheimer’s
and in blocking the loss of cognitive function in such mice. Nevertheless, in
the effort to ensure that the full value of the aminopyridazine technology
licensed from Northwestern University is fully realized, NeuroMedix is also
investigating additional clinical indications where Minozac has potential to
be effective through its action modulating neuroinflammation. These include
neuropathic pain, traumatic brain injury and multiple sclerosis.
About NeuroMedix:
NeuroMedix is a biotechnology company focused on the development of
therapeutic agents for the treatment of degenerative and inflammatory diseases
of the central nervous system, such as Alzheimer’s disease, multiple sclerosis
and Parkinson’s disease. Our therapeutic drug candidates are based on research
from a team of leading experts in the field of neuroinflammation at
Northwestern University and have been demonstrated to reduce brain
inflammation, to protect neuronal cells, and to prevent the loss of cognitive
function in an Alzheimer’s disease animal model in mice. Based on these
findings, NeuroMedix is pursuing the development of a lead compound for the
prevention of Alzheimer’s disease in humans. NeuroMedix’s shares are listed on
the TSX Venture Exchange under the symbol “NMX”.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
Except for historical information, this press release may contain
forward-looking statements, which reflect the Company’s current expectation
regarding future events. These forward-looking statements involve risks and
uncertainties, which may include but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company’s
ongoing quarterly and annual reporting.
%SEDAR: 00022976E
For further information: visit www.neuromedixinc.com or contact:
Mark Pearson, PhD., Chief Executive Officer, NeuroMedix Inc., (425) 503-5156,
mark@neuromedixinc.com or Catherine Auld, CA, Chief Financial Officer,
NeuroMedix Inc., (416) 673-8190, cathy@neuromedixinc.com
Source : http://www.newswire.ca/en/releases/archive/May2006/03/c3046.html
